Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SRA's number for the day: 2

This article was originally published in SRA

Executive Summary

The Pharmacopeial Discussion Group, which is working on harmonizing pharmacopeial standards in Japan, Europe and the US, agreed to harmonize two new excipient monographs (isomalt and hydroxypropylcellulose) during its meeting in Strasbourg, France, on 26-27 June 20131.

You may also be interested in...

Takeda’s CMV Infection ‘Game-Changer’ Among EU Fast-Track Hopefuls

Takeda, Calliditas and Bayer are set to learn whether the European Medicines Agency will grant their respective products accelerated assessment status when they file for pan-EU marketing approval.

NICE Funding Wins For Enhertu & Kesimpta Are Firsts For England

UK health technology assessment body NICE has struck deals with the makers of Enhertu for advanced breast cancer and Kesimpta for relapsing forms of multiple sclerosis.

Leo’s Tralokinumab Among 11 New Approval Hopefuls In EU

The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts